PMID: 18729013Aug 30, 2008Paper

Development of proteasome inhibitors in oncology and autoimmune diseases

Current Opinion in Drug Discovery & Development
Mark K Bennett, Christopher J Kirk

Abstract

The proteasome is a multicatalytic protease complex that mediates the controlled degradation of intracellular proteins, including key components of pathways that contribute to cancer cell growth and immune cell signaling. Validation for the proteasome as a therapeutic target in oncology was provided by bortezomib, a proteasome inhibitor that was approved for the treatment of multiple myeloma in 2003. Since that time, a number of structurally and mechanistically distinct proteasome inhibitors have entered clinical development in oncology. In this review, the chemical properties, preclinical antitumor activities and early clinical trials of these next-generation proteasome inhibitors are described and the potential for future proteasome inhibitor development in autoimmune indications is discussed.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Yasushi SaekiKeiji Tanaka
Frontiers in Bioscience : a Journal and Virtual Library
Lisa J A CrawfordAlexandra E Irvine
Annual Review of Pharmacology and Toxicology
Peter M Voorhees, Robert Z Orlowski
Nihon rinsho. Japanese journal of clinical medicine
Yorifumi Satou, Masao Matsuoka
© 2022 Meta ULC. All rights reserved